BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics after 1 Year
Resumen: Previous studies have indicated systemic deregulation of the proinflammatory or anti-inflammatory balance in individuals with first-episode psychosis (FEP) that persists 12 months later. To identify potential risk/protective factors and associations with symptom severity, we assessed possible changes in plasma levels of neurotrophins (brain-derived neurotrophic factor BDNF] and nerve growth factor NGF]) and their receptors in peripheral blood mononuclear cells (PBMCs). Expression of the 2 forms of BDNF receptors (active TrkB-FL and inactiveTrkB-T1) in PBMCs of FEP patients changed over time, TrkB-FL expression increasing by 1 year after diagnosis, while TrkB-T1 expression decreased. The TrkB-FL/TrkB-T1 ratio (hereafter FL/T1 ratio) increased during follow-up in the nonaffective psychosis group only, suggesting different underlying pathophysiological mechanisms in subgroups of FEP patients. Further, the expression of the main NGF receptor, TrkA, generally increased in patients at follow-up. After adjusting for potential confounders, baseline levels of inducible isoforms of nitric oxide synthase, cyclooxygenase, and nuclear transcription factor were significantly associated with the FL/T1 ratio, suggesting that more inflammation is associated with higher values of this ratio. Interestingly, the FL/T1 ratio might have a role as a predictor of functioning, a regression model of functioning at 1 year suggesting that the effect of the FL/T1 ratio at baseline on functioning at 1 year depended on whether patients were treated with antipsychotics. These findings may have translational relevance; specifically, it might be useful to assess the expression of TrkB receptor isoforms before initiating antipsychotic treatment in FEPs.
Idioma: Inglés
DOI: 10.1093/schbul/sbv078
Año: 2016
Publicado en: SCHIZOPHRENIA BULLETIN 42, 1 (2016), 142-151
ISSN: 0586-7614

Factor impacto JCR: 7.575 (2016)
Categ. JCR: PSYCHIATRY rank: 6 / 139 = 0.043 (2016) - Q1 - T1
Categ. JCR: PSYCHOLOGY, EXPERIMENTAL rank: 8 / 142 = 0.056 (2016) - Q1 - T1

Factor impacto SCIMAGO: 4.121 - Psychiatry and Mental Health (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PI10-01746
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PI11-01977
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PI11-02708
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/PI12-02077
Financiación: info:eu-repo/grantAgreement/ES/MINECO-ISCIII/CIBERSAM
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.


Exportado de SIDERAL (2020-02-21-13:23:47)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2017-05-11, last modified 2020-02-21


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)